KM analysis of OS by patient and disease characteristics in older AML population
| . | Univariate K-M survival analysis of OS (N = 200) . | Multivariate Cox regression for predictors of OS (N = 157) . | ||||
|---|---|---|---|---|---|---|
| Variable . | No. of deaths . | Median OS (mo) . | P . | HR . | 95% CI . | P . |
| Overall | 169/200 | 4.7 | — | |||
| Treatment group | ||||||
| High intensity | 32/33 | 3.48 | .22 | |||
| Intermediate intensity | 10/14 | 9.19 | ||||
| INV/low intensity | 127/143 | 4.99 | ||||
| Cyto group | ||||||
| Adverse | 69/79 | 3.08 | .005 | 1.65 | 1.09-2.61 | .018 |
| Nonadverse | 51/60 | 6.89 | ||||
| Age, y | ||||||
| 60-70 | 70/84 | 4.89 | .05 | |||
| >70 | 99/116 | 4.69 | ||||
| AHD type | ||||||
| MDS | 157/182 | 4.76 | .42 | |||
| Non-MDS | 12/18 | 4.4 | ||||
| t-AML status | ||||||
| Yes | 34/39 | 5.09 | .72 | |||
| No | 135/161 | 4.59 | ||||
| WBC* | ||||||
| <10 | 100/119 | 5.4 | .03 | 0.57 | 0.36-0.93 | .02 |
| ≥10 | 33/38 | 4.3 | ||||
| Platelet* | ||||||
| ≥50 | 87/103 | 4.3 | .03 | |||
| <50 | 46/54 | 5.7 | ||||
| BM-blast | ||||||
| <30% | 68/82 | 5.6 | .13 | |||
| ≥30% | 98/114 | 3.9 | ||||
| AHD therapy | ||||||
| HMA/lenalidomide/ thalidomide | 147/177 | 4.69 | .60 | |||
| Other | 22/26 | 5.02 | ||||
| . | Univariate K-M survival analysis of OS (N = 200) . | Multivariate Cox regression for predictors of OS (N = 157) . | ||||
|---|---|---|---|---|---|---|
| Variable . | No. of deaths . | Median OS (mo) . | P . | HR . | 95% CI . | P . |
| Overall | 169/200 | 4.7 | — | |||
| Treatment group | ||||||
| High intensity | 32/33 | 3.48 | .22 | |||
| Intermediate intensity | 10/14 | 9.19 | ||||
| INV/low intensity | 127/143 | 4.99 | ||||
| Cyto group | ||||||
| Adverse | 69/79 | 3.08 | .005 | 1.65 | 1.09-2.61 | .018 |
| Nonadverse | 51/60 | 6.89 | ||||
| Age, y | ||||||
| 60-70 | 70/84 | 4.89 | .05 | |||
| >70 | 99/116 | 4.69 | ||||
| AHD type | ||||||
| MDS | 157/182 | 4.76 | .42 | |||
| Non-MDS | 12/18 | 4.4 | ||||
| t-AML status | ||||||
| Yes | 34/39 | 5.09 | .72 | |||
| No | 135/161 | 4.59 | ||||
| WBC* | ||||||
| <10 | 100/119 | 5.4 | .03 | 0.57 | 0.36-0.93 | .02 |
| ≥10 | 33/38 | 4.3 | ||||
| Platelet* | ||||||
| ≥50 | 87/103 | 4.3 | .03 | |||
| <50 | 46/54 | 5.7 | ||||
| BM-blast | ||||||
| <30% | 68/82 | 5.6 | .13 | |||
| ≥30% | 98/114 | 3.9 | ||||
| AHD therapy | ||||||
| HMA/lenalidomide/ thalidomide | 147/177 | 4.69 | .60 | |||
| Other | 22/26 | 5.02 | ||||
Data available on baseline WBC and platelets in 157 of 200 evaluable patients.